McKesson Specialty Health completed the acquisition of RXC Acquisition Company from CVS Health Corporation.

McKesson Specialty Health entered into a definitive agreement to acquire RXC Acquisition Company from CVS Health Corporation (NYSE:CVS) for approximately $740 million on November 6, 2017. The purchase price is subject to a working capital adjustment and will be funded by cash on hand. The transaction is subject to customary closing conditions, including necessary regulatory clearances. The acquisition is expected to close in the fourth quarter of fiscal 2018. McKesson expects the impact of this transaction to be approximately $0.2 accretive to adjusted earnings per diluted share by the third year following the close of the transaction. Alan F. Denenberg, Jason Bassetti, Neil Barr, Patrick E. Sigmon, Tracy L. Matlock, Michele Ontiveros Gross, Jason J. Bang and Cynthia Akard of Davis Polk & Wardwell LLP acted as legal advisors to McKesson Corporation. Barclays Capital Inc. acted as financial advisor for CVS Health Corporation (NYSE:CVS). Ryan Thomas Bray, Jeremy Warren Cleveland, Marc Steven Elzweig, Chelsea Gunter, Christopher T. Hines, Mehran Massih, Kotoe Oshima, Anusha Pamula, Benjamin Andrew Petersen, Olcott Dillon Smith, Christopher E.Tomlinson, Matthew Allen Weston , Robert Katz, Laurence Crouch and Doreen Lilienfeld of Shearman & Sterling LLP and Dechert LLP acted as a Legal Advisor to CVS Health Corporation. McKesson Specialty Health completed the acquisition of RXC Acquisition Company from CVS Health Corporation (NYSE:CVS) on January 2, 2018. RXC Acquisition has become a part of McKesson Specialty Health business.